These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

362 related articles for article (PubMed ID: 27920704)

  • 1. Autoimmune Hemolytic Anemia as a Complication of Nivolumab Therapy.
    Palla AR; Kennedy D; Mosharraf H; Doll D
    Case Rep Oncol; 2016; 9(3):691-697. PubMed ID: 27920704
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Checkpoint inhibitors: the new treatment paradigm for urothelial bladder cancer.
    Katz H; Wassie E; Alsharedi M
    Med Oncol; 2017 Sep; 34(10):170. PubMed ID: 28864844
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The Next Immune-Checkpoint Inhibitors: PD-1/PD-L1 Blockade in Melanoma.
    Mahoney KM; Freeman GJ; McDermott DF
    Clin Ther; 2015 Apr; 37(4):764-82. PubMed ID: 25823918
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Autoimmune hemolytic anemia associated with the use of immune checkpoint inhibitors for cancer: 68 cases from the Food and Drug Administration database and review.
    Tanios GE; Doley PB; Munker R
    Eur J Haematol; 2019 Feb; 102(2):157-162. PubMed ID: 30347480
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Autoimmune Encephalitis After Treatment of Hodgkin's Lymphoma with the Immune Checkpoint Inhibitor Nivolumab.
    Nalbantoğlu M; Altunrende B; Tunçer ÖG; Akman G
    Noro Psikiyatr Ars; 2021 Jun; 58(2):163-165. PubMed ID: 34188600
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Targeting the PD-1 pathway: a new hope for gastrointestinal cancers.
    Bilgin B; Sendur MA; Bülent Akıncı M; Şener Dede D; Yalçın B
    Curr Med Res Opin; 2017 Apr; 33(4):749-759. PubMed ID: 28055269
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Nivolumab-induced autoimmune diabetes mellitus presenting as diabetic ketoacidosis in a patient with metastatic lung cancer.
    Godwin JL; Jaggi S; Sirisena I; Sharda P; Rao AD; Mehra R; Veloski C
    J Immunother Cancer; 2017; 5():40. PubMed ID: 28515940
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immunotherapy-associated autoimmune hemolytic anemia.
    Khan U; Ali F; Khurram MS; Zaka A; Hadid T
    J Immunother Cancer; 2017; 5():15. PubMed ID: 28239468
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Autoimmune hemolytic anemia after nivolumab treatment in Hodgkin lymphoma responsive to immunosuppressive treatment. A case report.
    Tardy MP; Gastaud L; Boscagli A; Peyrade F; Gallamini A; Thyss A
    Hematol Oncol; 2017 Dec; 35(4):875-877. PubMed ID: 27539158
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Principles of prophylactic and therapeutic management of skin toxicity during treatment with checkpoint inhibitors.
    Kamińska-Winciorek G; Cybulska-Stopa B; Lugowska I; Ziobro M; Rutkowski P
    Postepy Dermatol Alergol; 2019 Aug; 36(4):382-391. PubMed ID: 31616210
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Acute heart failure due to autoimmune myocarditis under pembrolizumab treatment for metastatic melanoma.
    Läubli H; Balmelli C; Bossard M; Pfister O; Glatz K; Zippelius A
    J Immunother Cancer; 2015; 3():11. PubMed ID: 25901283
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A case of pure red cell aplasia during nivolumab therapy for cardiac metastatic melanoma.
    Yuki A; Takenouchi T; Takatsuka S; Ishiguro T
    Melanoma Res; 2017 Dec; 27(6):635-637. PubMed ID: 28872489
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immunotherapy in head and neck cancer: aiming at EXTREME precision.
    Szturz P; Vermorken JB
    BMC Med; 2017 Jun; 15(1):110. PubMed ID: 28571578
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Check point inhibitors a new era in renal cell carcinoma treatment.
    Alsharedi M; Katz H
    Med Oncol; 2018 May; 35(6):85. PubMed ID: 29728867
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Nivolumab-related severe thrombocytopenia in a patient with relapsed lung adenocarcinoma: a case report and review of the literature.
    Hasegawa T; Ozaki Y; Inoue T; Watanabe Y; Fukuhara M; Yamaura T; Muto S; Okabe N; Higuchi M; Shio Y; Suzuki H
    J Med Case Rep; 2019 Oct; 13(1):316. PubMed ID: 31647029
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Isolated adrenocorticotropic hormone deficiency and thyroiditis associated with nivolumab therapy in a patient with advanced lung adenocarcinoma: a case report and review of the literature.
    Ohara N; Kobayashi M; Ohashi K; Ito R; Ikeda Y; Kawaguchi G; Yoneoka Y; Hasegawa G; Takada T
    J Med Case Rep; 2019 Mar; 13(1):88. PubMed ID: 30909965
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A systematic review of the cost and cost-effectiveness studies of immune checkpoint inhibitors.
    Verma V; Sprave T; Haque W; Simone CB; Chang JY; Welsh JW; Thomas CR
    J Immunother Cancer; 2018 Nov; 6(1):128. PubMed ID: 30470252
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Complete Local and Abscopal Responses from a Combination of Radiation and Nivolumab in Refractory Hodgkin's Lymphoma.
    Qin Q; Nan X; Miller T; Fisher R; Teh B; Pandita S; Farach AM; Pingali SR; Pandita RK; Butler EB; Pandita TK; Iyer SP
    Radiat Res; 2018 Sep; 190(3):322-329. PubMed ID: 29949442
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Seronegative autoimmune autonomic ganglionopathy from dual immune checkpoint inhibition in a patient with metastatic melanoma.
    Gao CA; Weber UM; Peixoto AJ; Weiss SA
    J Immunother Cancer; 2019 Oct; 7(1):262. PubMed ID: 31623673
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Nivolumab for the treatment of hepatocellular carcinoma.
    Finkelmeier F; Waidmann O; Trojan J
    Expert Rev Anticancer Ther; 2018 Dec; 18(12):1169-1175. PubMed ID: 30304963
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.